SPDR S&P Biotech ETF
431 hedge funds and large institutions have $5.76B invested in SPDR S&P Biotech ETF in 2018 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 153 increasing their positions, 123 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
431
Holders Change
+17
Holders Change %
+4.11%
% of All Funds
9.88%
Holding in Top 10
22
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+15.79%
% of All Funds
0.5%
New
64
Increased
153
Reduced
123
Closed
43
Calls
$1.36B
Puts
$1.9B
Net Calls
-$540M
Net Calls Change
+$387M
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$194M |
| 2 |
Morgan Stanley
New York
|
+$175M |
| 3 |
AssetMark Inc
Concord,
California
|
+$120M |
| 4 |
Goldman Sachs
New York
|
+$98.1M |
| 5 |
SG Americas Securities
New York
|
+$57.2M |
Top Sellers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$192M |
| 2 |
Rafferty Asset Management
New York
|
-$102M |
| 3 |
Citigroup
New York
|
-$78.1M |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$71.6M |
| 5 |
NM
NWI Management
New York
|
-$52.6M |
